Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 08, 2019

SELL
$3.76 - $14.16 $42,018 - $158,238
-11,175 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$8.27 - $13.56 $124,050 - $203,400
-15,000 Reduced 57.31%
11,175 $152,000
Q2 2018

Aug 13, 2018

BUY
$10.42 - $13.74 $272,743 - $359,644
26,175 New
26,175 $311,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $98M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Tocqueville Asset Management L.P. Portfolio

Follow Tocqueville Asset Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Tocqueville Asset Management L.P. with notifications on news.